The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Dariusz Kowalski
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Johnson & Johnson/Janssen; Merck Serono; MSD; Pfizer; Roche/Genentech; Sanofi/Aventis; Takeda
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Aitana Calvo
No Relationships to Disclose
 
Fiona Thistlethwaite
Honoraria - Bayer
Consulting or Advisory Role - Bristol-Myers Squibb; Enara Bio; GlaxoSmithKline; Guidepoint Pharmacy; Immatics; Ixaka; Janssen; Leucid Bio; Pfizer (Inst); Scenic Biotech; T-Knife
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Ixaka; Scenic Biotech
Other Relationship - iMatch
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Benevolent AI; Biosceptre; Bristol-Myers Squibb/Medarex; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Genmab; Immunocore; Incyte; Medivir; Nerviano Medical Sciences; Novartis; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
Other Relationship - Alligator Bioscience; AstraZeneca; GlaxoSmithKline; Sotio
 
Kevin Tianxiang Han
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
John Loffredo
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Jenna Carcione
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Daniel Jonathan
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Vinod Philip
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Mahadi Baig
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Peter Hellemans
Employment - Janssen
Leadership - Janssen
Honoraria - Janssen
 
Iurie Bulat
No Relationships to Disclose